stockrowPharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Return on equity
Pharvaris N.V.'s return on equity over the twelve months to 30 June 2026 was −71.5%, down 4.9 percentage points from fiscal 2025 (−66.6%). Over the past ten years it has ranged from −67.9% (fiscal 2019) to −28.7% (fiscal 2021); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −66.6% | (25.45) |
| FY2024 | −41.2% | (3.07) |
| FY2023 | −38.1% | 2.13 |
| FY2022 | −40.2% | (11.51) |
| FY2021 | −28.7% | 16.84 |
| FY2020 | −45.6% | 22.31 |
| FY2019 | −67.9% | (29.43) |
| FY2018 | −38.5% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| ADMA ADMA Biologics Inc compare | 42.0% |
| VCEL Vericel Corporation compare | 9.44% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −30.2% |
| CLDX Celldex Therapeutics, Inc. compare | −43.9% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −48.7% |
| IMNM Immunome, Inc. compare | −64.0% |
| PHVS Pharvaris N.V. | −71.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)